INTRODUCTION:Aripiprazole is a novel second-generation antipsychotic approved for the treatment of bipolar disorder in adults but there is no systematic data available in pediatric bipolar disorder. METHODS: This was an 8-week, open-label, prospective study of aripiprazole 9.4+/-4.2 mg/day monotherapy to assess the efficacy and tolerability of this compound in treating pediatric bipolar disorder. Assessments included the Young Mania Rating Scale, Clinical Global Impressions-Improvement scale, and Brief Psychiatric Rating Scale. Adverse events were assessed through spontaneous self-reports, vital signs weight monitoring, and laboratory analysis. RESULTS:Fifteen of the 19 bipolar youth (79%) completed the study. Aripiprazole treatment was associated with clinically and statistically significant improvement in mean Young Mania Rating Scale scores (-18.0+/-6.9, P<.0001). With the important exception of two cases of extrapyramidal symptoms that precipitated dropout, aripiprazole was well tolerated with no statistically significant increase in body weight (1.8+/-1.7 kg, P=.2). CONCLUSION:Open-label aripiprazole treatment was beneficial in the treatment of mania in youth with bipolar disorder. Future placebo-controlled, double-blind studies are warranted.
RCT Entities:
INTRODUCTION:Aripiprazole is a novel second-generation antipsychotic approved for the treatment of bipolar disorder in adults but there is no systematic data available in pediatric bipolar disorder. METHODS: This was an 8-week, open-label, prospective study of aripiprazole 9.4+/-4.2 mg/day monotherapy to assess the efficacy and tolerability of this compound in treating pediatric bipolar disorder. Assessments included the Young Mania Rating Scale, Clinical Global Impressions-Improvement scale, and Brief Psychiatric Rating Scale. Adverse events were assessed through spontaneous self-reports, vital signs weight monitoring, and laboratory analysis. RESULTS: Fifteen of the 19 bipolar youth (79%) completed the study. Aripiprazole treatment was associated with clinically and statistically significant improvement in mean Young Mania Rating Scale scores (-18.0+/-6.9, P<.0001). With the important exception of two cases of extrapyramidal symptoms that precipitated dropout, aripiprazole was well tolerated with no statistically significant increase in body weight (1.8+/-1.7 kg, P=.2). CONCLUSION: Open-label aripiprazole treatment was beneficial in the treatment of mania in youth with bipolar disorder. Future placebo-controlled, double-blind studies are warranted.
Authors: Janet Wozniak; Carter R Petty; Meghan Schreck; Alana Moses; Stephen V Faraone; Joseph Biederman Journal: J Psychiatr Res Date: 2011-06-17 Impact factor: 4.791
Authors: Kimberly A Stigler; Jonathan T Diener; Arlene E Kohn; Lang Li; Craig A Erickson; David J Posey; Christopher J McDougle Journal: J Child Adolesc Psychopharmacol Date: 2009-06 Impact factor: 2.576
Authors: Mona P Potter; Howard Y Liu; Michael C Monuteaux; Carly S Henderson; Janet Wozniak; Timothy E Wilens; Joseph Biederman Journal: J Child Adolesc Psychopharmacol Date: 2009-10 Impact factor: 2.576
Authors: Gagan Joshi; Carter Petty; Janet Wozniak; Stephen V Faraone; Andrea E Spencer; K Yvonne Woodworth; Rachel Shelley-Abrahamson; Hannah McKillop; Stephannie L Furtak; Joseph Biederman Journal: Psychopharmacology (Berl) Date: 2013-02-09 Impact factor: 4.530
Authors: José María Martínez-Ortega; Silvia Funes-Godoy; Francisco Díaz-Atienza; Luis Gutiérrez-Rojas; Lucía Pérez-Costillas; Manuel Gurpegui Journal: Eur Child Adolesc Psychiatry Date: 2013-03-17 Impact factor: 4.785